Evidence-Based Medicine Guidelines
Anti-angiogenic therapies for metastatic colorectal cancer
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Anti-angiogenic Therapies for Metastatic Colorectal Cancer." Evidence-Based Medicine Guidelines, John Wiley & Sons, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/452952/all/Anti_angiogenic_therapies_for_metastatic_colorectal_cancer.
Anti-angiogenic therapies for metastatic colorectal cancer. Evidence-Based Medicine Guidelines. John Wiley & Sons; 2025. https://evidence.unboundmedicine.com/evidence/view/EBMG/452952/all/Anti_angiogenic_therapies_for_metastatic_colorectal_cancer. Accessed March 26, 2025.
Anti-angiogenic therapies for metastatic colorectal cancer. (2025). In Evidence-Based Medicine Guidelines. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/EBMG/452952/all/Anti_angiogenic_therapies_for_metastatic_colorectal_cancer
Anti-angiogenic Therapies for Metastatic Colorectal Cancer [Internet]. In: Evidence-Based Medicine Guidelines. John Wiley & Sons; 2025. [cited 2025 March 26]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/452952/all/Anti_angiogenic_therapies_for_metastatic_colorectal_cancer.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Anti-angiogenic therapies for metastatic colorectal cancer
ID - 452952
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/452952/all/Anti_angiogenic_therapies_for_metastatic_colorectal_cancer
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
